title: Consolidation of first remission using radioimmunotherapy with yttrium-90-ibritumomab-tiuxetan in adult patients with Burkitt lymphoma.
abstract: The addition of anti-CD20 antibodies to high intensity polychemotherapy regimens has improved response and survival rates in newly diagnosed patients with Burkitt lymphoma (BL). However, the role of additional anti-CD20 directed radioimmunotherapy for consolidation of first remission (CR1) has not been reported so far in BL patients receiving rituximab during first-line treatment. We compared five BL patients receiving Y-90-IT radioimmunotherapy consolidation in CR1 to 22 consecutive BL patients without consolidation. We observed that Y-90-IT treatment was associated with clinically relevant myelosuppression. After a median follow-up of 50 months, none of the patients with Y-90-IT treatment relapsed, and no patient died. In contrast, one patient (4.5%) in the non-Y-90-IT group relapsed (50 months-PFS 95.5%; p=0.6336), and one patient died (50 months-OS 95.5%; p=0.6171). In conclusion, our data suggest that survival rates are excellent and equal in rituximab pretreated BL patients with or without Y-90-IT consolidation in first remission.
authors.affiliation: Department of Medical Oncology, University Hospital/Inselspital, Bern, Switzerland.
authors.forename: Valentin
authors.initials: V
authors.lastname: Koechli
authors.affiliation: Department of Nuclear Medicine, University Hospital/Inselspital, Bern, Switzerland.
authors.forename: Bernd
authors.initials: B
authors.lastname: Klaeser
authors.affiliation: Department of Pathology, University of Bern, Bern, Switzerland.
authors.forename: Yara
authors.initials: Y
authors.lastname: Banz
authors.affiliation: Department of Clinical Research, University of Bern, Bern, Switzerland.
authors.forename: Beatrice U
authors.initials: BU
authors.lastname: Mueller
authors.affiliation: Department of Medical Oncology, University Hospital/Inselspital, Bern, Switzerland. Electronic address: thomas.pabst@insel.ch.
authors.forename: Thomas
authors.initials: T
authors.lastname: Pabst
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002051:Burkitt Lymphoma / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D016499:Radioimmunotherapy; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan
keywords: Burkitt lymphoma; Radioimmunotherapy; Rituximab; Yttrium-90-ibritumomab-tiuxetan; Zevalin